Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

Shaji K Kumar, E. Ma, A. E. Engebretson, F. K. Buadi, Martha Lacy, Angela Dispenzieri, M. S. Duh, M. H. Lafeuille, P. Lefebvre, W. Y. Cheng, K. Dea, D. Rembert, D. Patt, L. Niculescu, M. Quick, S Vincent Rajkumar

Research output: Contribution to journalArticle

10 Scopus citations
Original languageEnglish (US)
JournalLeukemia
DOIs
StateAccepted/In press - Aug 14 2015

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Kumar, S. K., Ma, E., Engebretson, A. E., Buadi, F. K., Lacy, M., Dispenzieri, A., Duh, M. S., Lafeuille, M. H., Lefebvre, P., Cheng, W. Y., Dea, K., Rembert, D., Patt, D., Niculescu, L., Quick, M., & Rajkumar, S. V. (Accepted/In press). Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. Leukemia. https://doi.org/10.1038/leu.2015.225